Omada Health Analysts Say 'Buy' — While It's Still Below IPO Price

Canaccord Genuity and Needham analysts initiate coverage of Omada Health Inc (NASDAQ:OMDA) with a Buy rating.

Canaccord Genuity analyst Richard Close assigns a price target of $27.

Needham analyst Ryan MacDonald assigns a price target of $23.

Check out other analyst stock ratings.

Canaccord Genuity: Omada’s AI virtual care platform is "differentiated in a competitive chronic-care market," Close said in his initiation note. The company ...